[Effect of antithrombin-III (AT-III) on intestinal epithelium changes related to obstructive icterus: experimental study in rats].
OBJECTIVE
Bacterial translocation leading to sepsis is increased by obstructive jaundice(OJ). Antithrombin III (ATIII) mediates the promotion of prostaglandin release, an inhibitor of leucocyte activation and downregulator of many proinflammatory cytokines. We investigated the effect of ATIII on histopatology and villus morphology of small intestine.


METHODS
We designed an experimental study with 40 rats who were divided into four groups. The first one (control, n = 10) received saline, the second (n = 10) included normal rats who received ATIII, the third group (n = 10) was rats with OJ (ligation of common bile duct), and the fourth group included OJ rats receiving AT-III. AT-III (100 UI/kg intraperitoneally) was started at the third day following bile duct ligation and repeated for 5 days. At the 8 day, rats were scarified and ileum was analysed. Histopathological assessments were performed, using a grading scheme ranging from 0 to 10 (Chui et al).


RESULTS
Median histological score was found to be 2 in group 1, 1.71 in group 2, 5.43 in group 3 and 2.71 in group 4. The difference between group 3 and 4 was statistically significant. Mucosal thicknesses and villus lengths were found significantly lower in OJ group. Mucosal thicknesses and villus lengths were significantly preserved in jaundiced + AT-III group.


CONCLUSIONS
ATIII demonstrated a salutary effect on the histopathological changes caused by the OJ and prevented the adverse effects on histopathological and morphological parameters in ileal mucosa.
Caglikulekci
M
M
Département de chirurgie générale, université de médecine de Mersin, Turquie.
Dirlik
M
M
Scatton
O
O
Cinel
I
I
Ozer
I
I
Cinel
L
L
Ocal
K
K
Aydin
S
S
D000818:Animals; D000990:Antithrombin III / Q000494:pharmacology / Q000627:therapeutic use*; D018988:Bacterial Translocation / Q000187:drug effects; D003135:Common Bile Duct / Q000601:surgery; D016207:Cytokines / Q000187:drug effects; D004195:Disease Models, Animal; D015536:Down-Regulation / Q000187:drug effects; D004353:Drug Evaluation, Preclinical; D019446:Endotoxemia / Q000209:etiology; D006471:Gastrointestinal Hemorrhage / Q000209:etiology; D006940:Hyperemia / Q000209:etiology; D007082:Ileum / Q000187:drug effects / Q000276:immunology / Q000473:pathology; D018928:Immunity, Mucosal / Q000187:drug effects / Q000276:immunology; D007249:Inflammation; D007413:Intestinal Mucosa / Q000187:drug effects / Q000276:immunology / Q000473:pathology; D041781:Jaundice, Obstructive / Q000150:complications / Q000188:drug therapy / Q000276:immunology / Q000473:pathology; D007962:Leukocytes / Q000187:drug effects; D008026:Ligation; D011453:Prostaglandins; D011897:Random Allocation; D051381:Rats; D017208:Rats, Wistar; D015842:Serine Proteinase Inhibitors / Q000494:pharmacology / Q000627:therapeutic use*; D012720:Severity of Illness Index
D016207:Cytokines; D011453:Prostaglandins; D015842:Serine Proteinase Inhibitors; D000990:Antithrombin III